The favorable results from the placebo-controlled FLOW trial, conducted with semaglutide 1.0 mg in patients with T2D and chronic kidney disesase (CKD), are about to be disclosed, while ongoing dedicated trials will further explore the effects of OW semaglutide 2.4 mg (NCT04889183) and tirzepatide (NCT05536804) on kidney function parameters in obese/overweight individuals at high risk of CKD progression regardless of T2D
PAE is a safe and effective treatment for BPH
Thymosin Beta 4 fragment as Ac-SDKP (acetylated), BPC-157 as arginate salt other ingredients: Delayed release vegetable capsule (hypromellose, gellan gum), microcrystalline cellulose, silicon dioxide and organic carnauba wax Take 1 capsules once or twice a day on an empty stomach 1
Molecular docking The design of new drugs relies heavily on molecular docking
This iron-chelating property contributes to inflammatory and immune regulation, promotes gut microbiota remodeling, and alleviates iron overload along with associated oxidative cellular stress
